- Home
- DMLP vs NVAX Comparison
DMLP vs NVAX Comparison
Compare DMLP & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DMLP
- NVAX
- Stock Information
- Founded
- DMLP 2003
- NVAX 1987
- Country
- DMLP United States
- NVAX United States
- Employees
- DMLP N/A
- NVAX N/A
- Industry
- DMLP Oil & Gas Production
- NVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DMLP Energy
- NVAX Health Care
- Exchange
- DMLP Nasdaq
- NVAX Nasdaq
- Market Cap
- DMLP 1.6B
- NVAX 1.4B
- IPO Year
- DMLP N/A
- NVAX 1995
- Fundamental
- Price
- DMLP $30.98
- NVAX $8.74
- Analyst Decision
- DMLP
- NVAX Buy
- Analyst Count
- DMLP 0
- NVAX 6
- Target Price
- DMLP N/A
- NVAX $17.83
- AVG Volume (30 Days)
- DMLP 185.2K
- NVAX 4.8M
- Earning Date
- DMLP 02-20-2025
- NVAX 02-26-2025
- Dividend Yield
- DMLP 10.46%
- NVAX N/A
- EPS Growth
- DMLP 4.55
- NVAX N/A
- EPS
- DMLP 2.78
- NVAX N/A
- Revenue
- DMLP $166,454,000.00
- NVAX $885,193,000.00
- Revenue This Year
- DMLP N/A
- NVAX N/A
- Revenue Next Year
- DMLP N/A
- NVAX N/A
- P/E Ratio
- DMLP $11.18
- NVAX N/A
- Revenue Growth
- DMLP 14.26
- NVAX N/A
- 52 Week Low
- DMLP $28.41
- NVAX $3.60
- 52 Week High
- DMLP $35.74
- NVAX $23.86
- Technical
- Relative Strength Index (RSI)
- DMLP 30.49
- NVAX 46.04
- Support Level
- DMLP $31.49
- NVAX $8.15
- Resistance Level
- DMLP $32.24
- NVAX $8.71
- Average True Range (ATR)
- DMLP 0.58
- NVAX 0.55
- MACD
- DMLP -0.21
- NVAX -0.07
- Stochastic Oscillator
- DMLP 23.20
- NVAX 24.85
About DMLP Dorchester Minerals L.P. Common Units Representing Limited Partnership Interests
Dorchester Minerals LP operates as the owner of producing and non-producing crude oil and natural gas mineral, royalty, overriding royalty, net profits and leasehold interests. The company generates revenues from royalties, net profits interests, lease bonus, and others. It has leasehold interests in approximately 592 counties and parishes in around 28 states.
About NVAX Novavax Inc.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.